Since FGFR signaling regulates the cell cycle through cyclin D1, preclinical studies have shown that in NSCLC models with FGF3/4/19/CCND1 amplification, LY2874455 and the CDK4/6 inhibitor abemaciclib exhibit synergistic effects and can reverse resistance; in estrogen receptor-positive breast cancer, both theoretical rationale and early clinical studies support the validity of triple combination therapy targeting ER, CDK4/6, and FGFR [330,331]. The gene discussed is CDK4; the disease is non-small cell lung carcinoma.